

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 November 2022 (03.11.2022)



(10) International Publication Number
WO 2022/229919 A2

(51) International Patent Classification:
C07K 14/705 (2006.01)

(21) International Application Number:
PCT/IB2022/053997

(22) International Filing Date:
29 April 2022 (29.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/182,156 30 April 2021 (30.04.2021) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **MAZOR, Yariv**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **WANG, Yue**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **MOODY, Gordon**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **MALHOTRA, Deepali**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **OVERSTREET, Michael**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **CLANCY-THOMPSON, Eleanor**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **LEE, Karin**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **PRYTS, Stacy**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **HAMMOND, Scott**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **REHFUSS, Patrick**; AstraZeneca Intellectual Property, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEREOF

(57) Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 ("PD-1") and T cell immunoreceptor with Ig and ITIM domains ("TIGIT"). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

WO 2022/229919 A2